Omeprazole Market size was valued at USD 1.13 billion in 2024 and is set to exceed USD 2.56 billion by 2037, expanding at over 6.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of omeprazole is estimated at USD 1.25 billion.
Increasing cases of chronic diseases globally are boosting market growth. As per a report generated by WHO, at the end of 2050 chronic diseases such as cancer, diabetes, and respiratory ailments will be responsible for a startling 90% of all global fatalities.
Positive results during the clinical trials of omeprazole in H. pylori elimination therapy are anticipated to increase the demand for omeprazole globally during the foreseen period. In order to treat Helicobacter pylori infection, RedHill Biopharma, for example, recently published the phase 3 findings of the Talicia capsule, which combines antibiotics and a proton pump inhibitor.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 1.13 billion |
|
Forecast Year Market Size (2037) |
USD 2.56 billion |
|
Regional Scope |
|
Dosage Form (Capsule, Tablet, Powder)
The capsule segment is expected to propel the omeprazole market growth in the forecast period. The capsule segment is expected to occupy 52% of the largest market share by 2037. Additionally, the capsule is expected to cross 1800 Million by the end of 2036. The tablets are easy to handle and inexpensive. Also, 2020 will see a 24% increase in total medication use to 4.5 trillion doses. More than half of the world's population will take more than one dose of medication per person per day, up from one-third in 2005, with India, China, Brazil, and Indonesia leading the way. This may result in the expansion of industry growth.
Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux, Erosive Esophagitis)
The duodenal ulcer category is expected to drive market growth. This category was leading the market in 2019 as well. Duodenal ulcers are most commonly observed in the age groups of 25-55 years. With age, the incidence of peptic ulcer increased to a peak of 28.8% in the 5th decade of life. Duodenal ulcers are thought to affect 5 to 15% of people in the West, according to numerous studies that have assessed their prevalence. These factors are driving the growth of this segment.
Our in-depth analysis of the global market includes the following segments:
|
Dosage Form |
|
|
Distribution Channel |
|
|
Indication |
|
North American Market Forecast
North America industry is set to dominate majority revenue share of 59% by 2037. In 2020 the region experienced the prevalence of H. pylori infection which causes ulcers. Additionally, peptic ulcers are prominent in the US, around 4.5 million individuals are affected yearly. Also, about 10% of the US population is affected by duodenal ulcers. For example, there is an online service that helps people save around 80% on their prescription costs by working with large pharmacies in the US. These key factors are bolstering the market growth of Omeprazole in the region.
APAC Market Statistics
Asia Pacific to hold a share of 28.6% by 2037. Market growth in the region is driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key market players to increase their product portfolio. Vonoprazan, a product that is FDA-cleared for the treatment of gastroesophageal reflux disease by Phantom Pharmaceutics, was made available to Japanese consumers and another Asian country in March 2022. In addition, with the increased demand for gastroesophageal disease treatment in the Asia region, a number of players have been expanding their presence there.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?